NASDAQ:CMRXChimerix Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chimerix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.14 +0.03 (+0.96 %) (As of 08/3/2020 04:00 PM ET) Add Compare Share Today's Range$3.05Now: $3.14▼$3.1850-Day Range$2.92MA: $3.22▼$3.7252-Week Range$1.19Now: $3.14▼$3.88Volume649,791 shsAverage Volume711,730 shsMarket Capitalization$194.46 millionP/E RatioN/ADividend YieldN/ABeta1.9 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection. The company has license agreements with ContraVir Pharmaceuticals for the development and commercialization of CMX157 for various antiviral indications; and Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Chimerix has a potential upside of 122.9% from its current price of $3.14.Amount of Analyst CoverageChimerix has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesChimerix has received 351 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChimerix has received 374 “underperform” votes. (Add your “underperform” vote.)Community SentimentChimerix has received 51.59% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Chimerix and other stocks. Vote “Outperform” if you believe CMRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CMRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Chimerix is held by insiders.Percentage Held by Institutions48.16% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to grow in the coming year, from ($0.88) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.51 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMRX Previous Symbol CUSIPN/A CIK1117480 Webwww.chimerix.com Phone919-806-1074Debt Debt-to-Equity RatioN/A Current Ratio15.98 Quick Ratio15.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.52 million Price / Sales15.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book1.75Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-112,580,000.00 Net Margins-923.87% Return on Equity-34.16% Return on Assets-31.11%Miscellaneous Employees82 Outstanding Shares61,930,000Market Cap$194.46 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable $3.14 +0.03 (+0.96 %) (As of 08/3/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CMRX News and Ratings via Email Sign-up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Chimerix (NASDAQ:CMRX) Frequently Asked Questions How has Chimerix's stock been impacted by COVID-19 (Coronavirus)? Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CMRX stock has increased by 118.1% and is now trading at $3.14. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Chimerix? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chimerix. When is Chimerix's next earnings date? Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Chimerix. How were Chimerix's earnings last quarter? Chimerix Inc (NASDAQ:CMRX) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. The biopharmaceutical company earned $1.24 million during the quarter, compared to analysts' expectations of $1.50 million. Chimerix had a negative return on equity of 34.16% and a negative net margin of 923.87%. View Chimerix's earnings history. What price target have analysts set for CMRX? 1 Wall Street analysts have issued 12-month target prices for Chimerix's shares. Their forecasts range from $7.00 to $7.00. On average, they expect Chimerix's share price to reach $7.00 in the next year. This suggests a possible upside of 122.9% from the stock's current price. View analysts' price targets for Chimerix. Has Chimerix been receiving favorable news coverage? Media stories about CMRX stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chimerix earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Chimerix. Are investors shorting Chimerix? Chimerix saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,250,000 shares, an increase of 5.0% from the June 30th total of 1,190,000 shares. Based on an average trading volume of 1,080,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 2.7% of the shares of the stock are short sold. View Chimerix's Current Options Chain. Who are some of Chimerix's key competitors? Some companies that are related to Chimerix include Assembly Biosciences (ASMB), Kura Oncology (KURA), Legend Biotech (AMTI), ImmunoGen (IMGN), Morphic (MORF), Omeros (OMER), Tricida (TCDA), ZIOPHARM Oncology (ZIOP), Frequency Therapeutics (FREQ), Akouos (AKUS), Homology Medicines (FIXX), ORIC Pharmaceuticals (ORIC), Eagle Pharmaceuticals (EGRX), Passage Bio (KROS) and Kadmon (KDMN). View all competitors. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Novavax (NVAX), Inovio Pharmaceuticals (INO), SLS International (SLS), Wynn Resorts (WYNN), Gilead Sciences (GILD), Opko Health (OPK) and Sorrento Therapeutics (SRNE). Who are Chimerix's key executives? Chimerix's management team includes the following people: Mr. Timothy W. Trost, Sr. VP, CFO & Corp. Sec. (Age 61)Dr. William Garrett Nichols M.D., MS, Chief Medical Officer (Age 50)Mr. Michael A. Sherman, CEO & Pres (Age 53)Dr. Roy W. Ware Ph.D., MBA, Chief Manufacturing & Technology OfficerDr. Randall Lanier Ph.D., Chief Science Officer What is Chimerix's stock symbol? Chimerix trades on the NASDAQ under the ticker symbol "CMRX." Who are Chimerix's major shareholders? Chimerix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include SG Americas Securities LLC (0.04%), UBS Group AG (0.03%) and Marquette Asset Management LLC (0.03%). Company insiders that own Chimerix stock include Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View institutional ownership trends for Chimerix. Which institutional investors are selling Chimerix stock? CMRX stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Marquette Asset Management LLC. View insider buying and selling activity for Chimerix. Which institutional investors are buying Chimerix stock? CMRX stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Martha J Demski, Michael A Sherman, Michael T Andriole, and Robert J Meyer. View insider buying and selling activity for Chimerix. How do I buy shares of Chimerix? Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Chimerix's stock price today? One share of CMRX stock can currently be purchased for approximately $3.14. How big of a company is Chimerix? Chimerix has a market capitalization of $194.46 million and generates $12.52 million in revenue each year. The biopharmaceutical company earns $-112,580,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Chimerix employs 82 workers across the globe. What is Chimerix's official website? The official website for Chimerix is www.chimerix.com. How can I contact Chimerix? Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-806-1074 or via email at [email protected] This page was last updated on 8/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
